跳至主要内容
临床试验/NCT00143091
NCT00143091终止2 期

A Six-Week, Fixed Dose, Double-Blind, Double-Dummy, Placebo and Sertraline Controlled, Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Outpatients With Major Depressive Disorder

Pfizer10 个研究点 分布在 4 个国家目标入组 200 人开始时间: 2005年4月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
终止
发起方
Pfizer
入组人数
200
试验地点
10
主要终点
Change from baseline in HAM-D (17) at the week 6 visit

研究概览

简要总结

A six week, fixed dose, double-blind, double-dummy, placebo, and active controlled, multicentre trial to evaluate the safety and efficacy of CP-316,311 in outpatients with major depressive disorder.

详细描述

This study was terminated on March 17th, 2006. The results of the primary analysis at the interim showed that the CP-316,311 group was not significantly different than the placebo on the primary endpoint and therefore the data monitoring committee recommended termination of the trial. The decision to terminate the trial was not based on any safety concerns.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Outpatients with DSM-IV major depressive disorder

排除标准

  • Women of child bearing potential

结局指标

主要结局

Change from baseline in HAM-D (17) at the week 6 visit

次要结局

  • Change from baseline in MADRS, HAM-A, CGI-S and CGI-I at the week 6 visit.

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (10)

Loading locations...

相似试验